Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

Issue 11, Drugs & Dealers Magazine Released

Biotech and Money are pleased to announce the release of the latest Drugs &...

Read More

Issue 10, 2016 Drugs & Dealers Magazine Released

Biotech and Money are pleased to announce the release of the latest Drugs &...

Read More

Inv€$table CEO Pitch Series: Emma Sceats, CEO of 2...

Straight from the Inv€$table CEO Pitch Breakfast hosted by K&L Gates on Tue...

Read More

Who will be debating the pros and cons of the Brex...

Today marks exactly 3 weeks until Britain makes one of its biggest decision...

Read More

Brexit: Leaving the EU could trigger UK science pa...

Some aspects of patent law of relevance to life sciences companies could co...

Read More

What would Brexit mean for the Pharma Industry?

The Conservatives' 2015 election manifesto committed to hold a referendum b...

Read More

A Breath of Fresh Air for the Global Respiratory M...

Dr. Jan-Anders Karlsson, CEO of Verona Pharma, shares company’s core focus ...

Read More

Birmingham is becoming a leading location for Life...

In an exclusive interview with Biotech and Money, Chris Yates,a prominent t...

Read More

Growing Life Sciences in Birmingham: The BioHub

James Wilkie, CEO of Birmingham Research Park,shines a spotlight on the Bir...

Read More

Medicxi launches GSK and J&J backed 210 million Eu...

Francesco de Rubertis, Co-Founder and Partner of Medicxi Ventures, talks to...

Read More

One Year on from IPO: Motif Bio’s Commercialisatio...

Graham Lumsden, CEO of Motif Bio, talks to Biotech and Money about the comm...

Read More

A Strategic Law Firm Central to the EU Tech & VC E...

Biotech and Money had the opportunity to talk with James Shaw, Co-Founder a...

Read More
  • Prev

Add Your Response